Clinical Trial Update: BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing afatinib (BIBW 2992) to chemotherapy as first-line treatment in EGFR-mutant non-small cell lung cancer has completed and results were po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma | Phase 3 | Status: COMPLETED | Results posted: 2013-11-19